NASDAQ:EPZM
Delisted
Epizyme Stock News
$1.47
+0 (+0%)
At Close: Nov 10, 2022
Epizyme to Participate in Jefferies Virtual Healthcare Conference
06:30am, Tuesday, 25'th May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Ro
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2021 Results - Earnings Call Transcript
03:19pm, Saturday, 08'th May 2021
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2021 Results - Earnings Call Transcript
EPZM Stock: 9.44% Decrease Explanation
08:56am, Friday, 07'th May 2021
The stock price of Epizyme Inc (NASDAQ: EPZM) decreased by 9.44% yesterday. This is why it happened.
SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug
08:44am, Friday, 07'th May 2021
Shares of Epizyme Inc. were up 11.0% in premarket trading on Friday after SVB Leerink upgraded the company's stock to outperform, from market perform, citing Tazverik's potential opportunity in the fo
Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
08:16am, Friday, 07'th May 2021
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
09:01am, Thursday, 06'th May 2021
Epizyme (EPZM) delivered earnings and revenue surprises of -23.21% and 7.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Epizyme Announces Date of First Quarter 2021 Financial Results
06:30am, Thursday, 29'th Apr 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that ma
Epizyme Comeback Is Likely, Price Makes It A Buy
04:14am, Tuesday, 30'th Mar 2021
Epizyme is at a multi-year low. Main cause of disappointment is slow sales of Tazverik. Potential is great with label expansion and epigenetic pipeline.
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company's Strategic Vision Call
12:00pm, Tuesday, 02'nd Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, hosted a call toda
Epizyme to Host Strategic Vision Call on March 2, 2021
06:30am, Wednesday, 24'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that it
Epizyme's (EPZM) CEO Rob Bazemore on Q4 2020 Results - Earnings Call Transcript
12:13pm, Tuesday, 23'rd Feb 2021
Epizyme's (EPZM) CEO Rob Bazemore on Q4 2020 Results - Earnings Call Transcript
Epizyme (EPZM) Reports Q4 Loss, Tops Revenue Estimates
08:20am, Tuesday, 23'rd Feb 2021
Epizyme (EPZM) delivered earnings and revenue surprises of -10.17% and 30.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Epizyme: Q4 Earnings Insights
07:24am, Tuesday, 23'rd Feb 2021
Shares of Epizyme (NASDAQ:EPZM) rose 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 10.17% over the past year to ($0.65), which missed
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
06:30am, Tuesday, 23'rd Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business
Epizyme (EPZM) Down 3.4% Since Last Earnings Report: Can It Rebound?
11:30am, Sunday, 06'th Dec 2020
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
